Dasatinib Drugs Market Report 2024

This Dasatinib Drugs market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The dasatinib drugs market size has grown strongly in recent years. It will grow from $1.36 billion in 2023 to $1.45 billion in 2024 at a compound annual growth rate (CAGR) of 6.6%. The growth observed in the historical period is largely due to the rising incidence of chronic myeloid leukemia (CML), advancements in targeted cancer therapies, increased research on tyrosine kinase inhibitors (TKIs), heightened investment in oncology research, and a growing number of clinical trials.

The dasatinib drugs market size is expected to see strong growth in the next few years. It will grow to $1.87 billion in 2028 at a compound annual growth rate (CAGR) of 6.7%. In the forecast period, growth can be attributed to a surge in investment in oncology drug development, an uptick in drug-resistant leukemia cases, greater availability of generic dasatinib drugs, a heightened focus on reducing chemotherapy side effects, and improved awareness and early detection of leukemia. Key trends expected during the forecast period include the rise of personalized medicine, the use of companion diagnostics, the creation of new formulations, progress in combination therapies, and the development of biosimilars.

The rising incidence of chronic myeloid leukemia (CML) is projected to drive growth in the dasatinib drug market in the coming years. CML is a cancer that impacts the bone marrow and blood, characterized by the abnormal proliferation of white blood cells. This increase in prevalence is largely influenced by lifestyle factors, poor dietary habits, and growing environmental risks. Dasatinib is effective in treating CML by inhibiting the BCR-ABL gene fusion, a tyrosine kinase protein resulting from the Philadelphia chromosome mutation that leads to uncontrolled white blood cell growth. For example, in January 2023, the American Cancer Society reported that the number of CML cases in the United States rose to 8,930, up from 8,860 in 2022. Thus, the increasing prevalence of CML is fueling the dasatinib drug market.

Key players in the dasatinib market are concentrating on the development of generic drugs to expand their market presence, provide affordable treatment options, and enhance patient accessibility. Generic versions of dasatinib improve affordability, thus facilitating greater access for patients and fostering competition that can help lower healthcare costs. For instance, in September 2024, Apotex Corp., a Canadian pharmaceutical company, launched the first generic version of Sprycel (dasatinib) in the United States for treating specific types of leukemia in both adults and children. This development significantly enhances access to effective treatments while promoting price competition in the dasatinib market.

In August 2022, Bristol-Myers Squibb, a U.S.-based pharmaceutical company, acquired Turning Point Therapeutics Inc. for $4.1 billion. This acquisition bolsters BMS's cancer treatment portfolio by adding innovative therapies that target genetic mutations, thereby strengthening its position in the competitive lung cancer treatment arena. Turning Point Therapeutics Inc. specializes in developing next-generation tyrosine kinase inhibitors, including dasatinib, aimed at providing targeted therapies for cancer patients.

Major companies operating in the dasatinib drugs market are Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Sandoz Group AG, Hetero Drugs Limited, Sun Pharmaceutical Industries Limited, MSN Laboratories Pvt. Ltd., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Limited, Intas Pharmaceuticals Ltd., Cipla Limited, Hikma Pharmaceuticals plc, Lupin Limited, Zhejiang Hisun Pharmaceutical Co. Ltd., Biocon Limited, Alkem Laboratories Limited, Glenmark Pharmaceuticals Limited, Torrent Pharmaceuticals Limited, Alembic Pharmaceuticals Limited, Mylan N.V., Manus Aktteva Biopharma LLP.

North America was the largest region in the dasatinib drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dasatinib drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the dasatinib drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Dasatinib medications are a form of targeted therapy classified as tyrosine kinase inhibitors, mainly utilized in the treatment of blood cancers such as chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). These drugs function by inhibiting proteins that promote cancer cell proliferation, which aids in slowing the progression of the disease. This results in enhanced survival rates and improved disease management.

The primary product types of dasatinib drugs include tablets, oral suspension, and other formulations. Dasatinib is predominantly available in tablet form, providing convenience for patients who need to take it orally. Its various applications encompass chronic myeloid leukemia, acute lymphoblastic leukemia, among others, with several end users such as hospitals, specialty clinics, and home healthcare providers.

The dasatinib drugs market research report is one of a series of new reports that provides dasatinib drugs market statistics, including dasatinib drugs industry global market size, regional shares, competitors with a dasatinib drugs market share, detailed dasatinib drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the dasatinib drugs industry. This dasatinib drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The dasatinib drugs market consists of sales of sprycel and generic dasatinib. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.